FI953369A0 - Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi - Google Patents

Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi

Info

Publication number
FI953369A0
FI953369A0 FI953369A FI953369A FI953369A0 FI 953369 A0 FI953369 A0 FI 953369A0 FI 953369 A FI953369 A FI 953369A FI 953369 A FI953369 A FI 953369A FI 953369 A0 FI953369 A0 FI 953369A0
Authority
FI
Finland
Prior art keywords
prevention
preparation
treatment
pharmaceutical compositions
cancer diseases
Prior art date
Application number
FI953369A
Other languages
English (en)
Swedish (sv)
Other versions
FI953369A (fi
Inventor
Gyula Kulcsar
Original Assignee
Immunal Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunal Kft filed Critical Immunal Kft
Publication of FI953369A0 publication Critical patent/FI953369A0/fi
Publication of FI953369A publication Critical patent/FI953369A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI953369A 1993-11-09 1995-07-07 Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi FI953369A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9303171A HU213677B (en) 1993-11-09 1993-11-09 Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
PCT/HU1994/000049 WO1995013061A1 (en) 1993-11-09 1994-11-08 Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation

Publications (2)

Publication Number Publication Date
FI953369A0 true FI953369A0 (fi) 1995-07-07
FI953369A FI953369A (fi) 1995-07-07

Family

ID=10984131

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953369A FI953369A (fi) 1993-11-09 1995-07-07 Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi

Country Status (18)

Country Link
EP (1) EP0679081B1 (fi)
JP (1) JPH08508045A (fi)
KR (1) KR100363779B1 (fi)
CN (1) CN1128615C (fi)
AT (1) AT408414B (fi)
AU (1) AU682735B2 (fi)
CA (1) CA2151826C (fi)
CH (1) CH686867A5 (fi)
CZ (1) CZ286633B6 (fi)
DE (2) DE4498692T1 (fi)
ES (1) ES2094702B1 (fi)
FI (1) FI953369A (fi)
HU (1) HU213677B (fi)
NL (1) NL195007C (fi)
PL (1) PL177981B1 (fi)
RU (1) RU2138257C1 (fi)
SE (1) SE521049C2 (fi)
WO (1) WO1995013061A1 (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864024A (en) * 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
AU6340198A (en) * 1997-03-04 1998-09-22 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resultingin chronic conditions
RU2108786C1 (ru) * 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2164013B1 (es) * 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
JPWO2003030890A1 (ja) * 2001-10-05 2005-02-10 哲朗 浅尾 免疫系活性化剤
EP1583543A4 (en) * 2002-01-16 2009-09-09 Eliezer Rapaport METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
US10016385B2 (en) * 2004-12-17 2018-07-10 Alan B. Cash Method for extending lifespan delaying the onset of age-related disease
EP1909804B1 (en) * 2005-08-03 2012-02-29 National Cancer Center Glucosamine and derivatives thereof useful as transglutaminase inhibitors in the treatment of a nervous system disorder
KR100878585B1 (ko) 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
WO2015137383A1 (ja) * 2014-03-11 2015-09-17 味の素株式会社 癌化学療法の補助剤
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE2021969A1 (de) * 1970-04-29 1971-11-18 Boettger Kg Pharmazeutische Un Verfahren zur Herstellung eiweissfreier Praeparate
FR2201879B2 (fi) * 1972-05-19 1976-01-23 Tixier Georges Fr
FR2244468A1 (en) * 1973-07-31 1975-04-18 Passwater Richard Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4880918A (en) * 1982-07-13 1989-11-14 Eliezer Rapaport Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability

Also Published As

Publication number Publication date
DE4498692T1 (de) 1996-02-22
SE521049C2 (sv) 2003-09-23
EP0679081A1 (en) 1995-11-02
EP0679081B1 (en) 2002-02-06
KR100363779B1 (ko) 2003-03-06
CN1116406A (zh) 1996-02-07
HU213677B (en) 1997-12-29
DE69429806D1 (de) 2002-03-21
CZ177395A3 (en) 1996-01-17
RU2138257C1 (ru) 1999-09-27
ATA900894A (de) 2001-04-15
SE9502474D0 (sv) 1995-07-06
FI953369A (fi) 1995-07-07
AU682735B2 (en) 1997-10-16
ES2094702B1 (es) 1998-02-16
SE9502474L (sv) 1995-07-06
AU1074995A (en) 1995-05-29
PL309600A1 (en) 1995-10-30
CN1128615C (zh) 2003-11-26
CA2151826A1 (en) 1995-05-18
CA2151826C (en) 2008-06-17
DE69429806T2 (de) 2002-09-12
NL195007C (nl) 2003-06-10
CZ286633B6 (cs) 2000-05-17
NL9420013A (nl) 1995-10-02
WO1995013061A1 (en) 1995-05-18
ES2094702A1 (es) 1997-01-16
HU9303171D0 (en) 1994-01-28
JPH08508045A (ja) 1996-08-27
PL177981B1 (pl) 2000-02-29
CH686867A5 (de) 1996-07-31
AT408414B (de) 2001-11-26

Similar Documents

Publication Publication Date Title
FI953369A0 (fi) Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi
FI941979A0 (fi) Farmaseuttiset tuotteet kasvainsairausten hoitamiseksi ja menetelmä niiden valmistamiseksi
FI880928A0 (fi) Menetelmä farmaseuttisen tabletin ja farmaseuttisen granulaatin valmistamiseksi
FI953056A (fi) Menetelmä farmaseuttisten koostumusten valmistamiseksi ultraäänen avulla
FI954383A (fi) Menetelmä syöpärokotteiden valmistamiseksi
FI97140B (fi) Menetelmä epäorgaanisen jauheen käsittelemiseksi
FI970918A0 (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
FI893520A (fi) Menetelmä intravenoosisen farmaseuttisen koostumuksen valmistamiseksi
FI900604A0 (fi) Menetelmä syklosporiinia sisältävän farmaseuttisen koostumuksen valmistamiseksi
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
FI941137A0 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI931657A0 (fi) Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
FI901787A0 (fi) Menetelmä lääkkeenvälityskoostumuksen valmistamiseksi
FI98046B (fi) Menetelmä syklosporiinia sisältävän farmaseuttisen koostumuksen valmistamiseksi
FI892640A0 (fi) Menetelmä piperidinoalkanoli-ibuprofeeniyhdistelmää sisältävän farmaseuttisen koostumuksen valmistamiseksi
AU4048295A (en) Peptide medicaments for the treatment of disease
FI962685A (fi) 2,3-diaryyli-1-bentsopyraanijohdannaisten käyttö lääkkeen valmistamiseksi luukadon ja osteoporoosin hoitamiseksi ja estämiseksi
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
EP0584034A3 (en) Conjugates of cytotoxic drugs for the treatment of neoplastic diseases.
FI942222A (fi) Menetelmä kuivakäsiteltyjen hiukkasten valmistamiseksi, näin saadut kuivakäsitellyt hiukkaset ja näitä hiukkasia sisältävät farmaseuttiset seokset
FI933477A (fi) Monohydrat av ett dinatriumsalt av 4-klorfenyltiometylenbisfosfonsyra,dess framstaellning och farmaceutiska kompositioner innehaollande detta
FI101452B1 (fi) Menetelmä tonsilliitin ennalta ehkäisyyn ja/tai hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
FI910967A (fi) Menetelmä bisfenoli A:n valmistamiseksi
HU9302906D0 (en) Pharmaceutical product for disease of respiratory organs
IL106751A0 (en) Pharmaceutical compositions for the treatment of reversible obstructive airways diseases

Legal Events

Date Code Title Description
FC Application refused
RF Appeal filed
FCK Appeal rejected

Free format text: APPLICATION REJECTED